Meta description this report covers a European trial evaluating cultured epithelial autografts and cultured dermal epidermal autografts for severe burns with regulatory relevance.
Publication date context February 19 2026. A European multi center trial examines cultured epithelial autografts and cultured dermal epidermal autografts in patients with severe burn injuries. The intervention is listed as standard of care and the study is not yet recruiting. Sponsor institutions include University Children’s Hospital Zurich University Hospital Zurich and Centre Hospitalier Universitaire Vaudois. The ClinicalTrials.gov entry NCT07415577 provides the registry details and confirms the sponsor sites and the broad burn conditions addressed including second degree burns third degree burns skin transplantation and full thickness skin defects. This article summarizes the available registry information and its potential implications for burn care governance and device regulation.
What is the study about?
The study focuses on the use of cultured epithelial autografts CEA and cultured dermal epidermal autografts CDEA in severely burned patients. The entry lists second degree burns and third degree burns as conditions of interest along with needs for skin transplantation and full thickness skin defects. The intervention is described as standard of care. Sponsoring institutions include University Children’s Hospital Zurich University Hospital Zurich and Centre Hospitalier Universitaire Vaudois. The trial status is not yet recruiting with the ClinicalTrials.gov identifier NCT07415577 serving as the registry reference. This summary reflects the information provided in the registry and its description of a burn care study conducted by Swiss centers.
What are CEA and CDEA in burn care?
Cultured epithelial autografts and cultured dermal epidermal autografts are mentioned in the registry as autograft based strategies for severe burns. The study frames these options within the context of existing wound care practices and graft based therapies. The emphasis is on applying these autograft based approaches to second and third degree burns and to wounds that involve full thickness skin defects. The description in the registry remains focused on intended use within current care pathways rather than signaling a new device classification at this stage.
Trial design and current status
The registry lists standard of care as the intervention which suggests alignment with established treatment pathways rather than testing a novel device in isolation. The entry confirms three sponsor sites in Switzerland and notes the status as not yet recruiting indicating that enrollment has not started. The NCT07415577 listing provides the official reference and a stable point for regulatory and health care teams to monitor. Readers should expect updates as enrollment and protocol details evolve as captured by ClinicalTrials.gov.
What are the regulatory implications for registered studies like this?
Studies that explore autograft based approaches in burn care must navigate the regulatory frameworks that govern advanced therapies and skin substitutes. The European setting with Swiss sponsors signals alignment with regional health care standards and regulatory expectations for clinical evaluation of regenerative wound therapies. While the current entry centers on not yet recruiting status with standard of care as the intervention future updates may describe participant criteria endpoints and safety considerations. Stakeholders including hospitals sponsors and device manufacturers should monitor the ClinicalTrials.gov entry for changes that can influence regulatory submissions ethical reviews and eventual market access considerations.
Why this matters for patients
For patients with severe burns the potential for autograft based options could broaden treatment choices and influence healing timelines. The trial indicates ongoing interest in integrating CEA and CDEA within established care pathways rather than replacing standard care. If updates move toward enrollment patients may have opportunities to participate in regenerative approaches under careful regulatory oversight. Clinicians and regulators should track the registry to align expectations with evidence generation and to inform future guidance for burn wound management and skin restoration technologies.
FAQ
- 1. What is being studied The registry describes the use of cultured epithelial autografts and cultured dermal epidermal autografts in severely burned patients as a not yet recruiting European trial.
- 2. Who are the sponsors The listed sponsors are University Children’s Hospital Zurich University Hospital Zurich and Centre Hospitalier Universitaire Vaudois in Switzerland.
- 3. What is the status The entry shows not yet recruiting status with ClinicalTrials.gov identifier NCT07415577.
Conclusion
This article presents a not yet recruiting European trial that assesses cultured epithelial autografts and cultured dermal epidermal autografts in the context of severe burn care with a standard of care approach. Stakeholders should monitor the ClinicalTrials.gov listing for updates on enrollment endpoints and safety parameters. The participating centers are Swiss institutions known for burn care excellence and the registry entry will guide future regulatory and clinical discussions on skin restoration therapies.
Disclaimer
This article is intended for professionals. It is not legal advice and does not constitute a regulatory decision or endorsement. Always consult official regulatory documents and the ClinicalTrials.gov entry for authoritative information.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07415577?term=medical+device